
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma is poised for success due to their innovative cell-free protein synthesis platform and the potential of their ADCs, especially STRO-004 and STRO-006, as promising treatments for solid tumors. With their strong pipeline and ongoing studies on combination therapies, the company is well-positioned to make a significant impact in the field of cancer treatment. The increase in price target and promising results from preclinical studies further support a positive outlook for Sutro Biopharma.
Bears say
Sutro Biopharma is a clinical-stage pharmaceutical company that specializes in the development of next-generation antibody-drug conjugates (ADCs) for solid tumors. While their proprietary platform and dual-payload ADCs have promising preclinical data, the technical challenges of linker chemistry and payload selection remain a concern. Additionally, the company's valuation is based on optimistic assumptions and there are significant risks that could prevent them from reaching their price target.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares